This is confirmation of a previously announced deal, not a fresh surprise. AtaiBeckley disclosed the Lilly merger on July 15, 2026, and the September 11 filing confirms that it closed on schedule. 〔0〕 Because the transaction terms were already public, the market had largely priced in this outcome; there is no clean beat-or-miss comparison.
Shareholders receive $6.75 per share immediately, with additional value dependent on development milestones. Each share converts into $6.75 in cash plus one CVR worth up to another $2.50 if specified VLS-01 and BPL-003 milestones are achieved. 〔1〕 The headline consideration is therefore $6.75 realized value, while the extra $2.50 is uncertain, non-transferable and not exchange-listed rather than cash delivered at closing.
The public-company investment case ends with the closing. AtaiBeckley became Lilly’s wholly owned subsidiary, its common stock trading was requested to be suspended, and Nasdaq delisting and termination of reporting obligations will follow.
Net read: in line and priced in. The filing delivers exactly the expected completion mechanics, with no new operating results, guidance change or deal-term improvement. The remaining investor-relevant catalyst is whether Lilly advances the programs far enough to trigger the CVR payments, beginning with potential Phase 3 initiation for VLS-01 by September 11, 2030.
Read the original 8-K on SEC EDGAR ↗